Among the Caucasians, activating mutations in FGFR3 have been earlier reported in bladder carcinoma [26], lung squamous cell carcinomas [20] and cervical cancer [27], but were found to be largely absent in lung adenocarcinomas [23, 28, 29], except for Imielinski et al. who reported non-recurrent somatic FGFR3 mutations of unknown functional significance in 3 of 183 lung adenocarcinoma patients [10]. Here, FGFR3 is linked to cervical cancer.